Chronic obstructive pulmonary disease and comorbidities

The Lancet Respiratory Medicine

Volumn 1, Issue 1, 2013, Pages 73-83

  Decramer, Marc ^a   Janssens, Wim ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BISPHOSPHONIC ACID DERIVATIVE; BRONCHODILATING AGENT; CALCIUM; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUTICASONE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE; MACROPHAGE ELASTASE; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; ROFLUMILAST; SALMETEROL; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA; VILANTEROL; VITAMIN D;

AGING; ARTERIAL STIFFNESS; B LYMPHOCYTE; CACHEXIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DIABETES MELLITUS; DIETARY INTAKE; DISEASE PREDISPOSITION; DRUG ACTIVITY; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; EPIGENETICS; FORCED EXPIRATORY VOLUME; GENE MUTATION; HEART INFARCTION; HEREDITY; HUMAN; IMMOBILIZATION; INCIDENCE; INSULIN RESISTANCE; LOW DRUG DOSE; LUNG CANCER; MACROPHAGE; METABOLIC SYNDROME X; MUSCLE WEAKNESS; NEUTROPHIL; ONCOGENE; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOKING; T LYMPHOCYTE; AGE; CARDIOVASCULAR DISEASES; LUNG NEOPLASMS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

AGE FACTORS; CARDIOVASCULAR DISEASES; COMORBIDITY; HUMANS; LUNG NEOPLASMS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84880040954     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(12)70060-7     Document Type: Review

References (131)

1. Bloom D, Cafiero E, Abrahams-Gessel S, et al. The global economic burden of non-communicable diseases: a report by the World Economic Forum and the Harvard School of Public Health, September 2011 2011, World Economic Forum, Geneva, Switzerland.
2. Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences-clinical impact, mechanisms, and potential for early intervention. COPD 2008, 5:235-256.
3. Mapel DW, Hurley JS, Frost FJ, et al. Health care utilization in chronic obstructive pulmonary disease: a case-control study in a health maintenance organization. Arch Intern Med 2000, 160:2653-2658.
4. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:155-161.
5. Patel AR, Hurst JR Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med 2011, 5:647-662.
6. McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007, 62:411-415.
7. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008, 32:962-969.
8. Zielinski J, MacNee W, Wedzicha J, et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997, 52:43-47.
9. Mannino DM, Doherty DE, Sonia BA Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006, 100:115-122.
10. Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006, 28:1245-1257.
11. Sin DD, Wu L, Man SF The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005, 127:1952-1959.
12. Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010, 65:956-962.
13. Mills NL, Miller JJ, Anand A, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax 2008, 63:306-311.
14. McAllister DA, Maclay JD, Mills NL, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176:1208-1214.
15. Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009, 122:348-355.
16. Cazzola M, Bettoncelli G, Sessa E, et al. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010, 80:112-119.
17. Sode BF, Dahl M, Nordestgaard BG Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7·4 million individuals. Eur Heart J 2011, 32:2365-2375.
18. van den Borst B, Gosker HR, Zeegers MP, et al. Pulmonary function in diabetes: a meta-analysis. Chest 2010, 138:393-406.
19. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet 2007, 370:741-750. for the BOLD Collaborative Research Group.
20. Pope CA, Burnett RT, Turner MC, et al. Lung cancer and cardiovascular disease mortality associated with ambient air pollution and cigarette smoke: shape of the exposure-response relationships. Environ Health Perspect 2011, 119:1616-1621.
21. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653.
22. Suwa T, Hogg JC, Quinlan KB, et al. Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol 2002, 39:935-942.
23. Terashima T, Klut ME, English D, et al. Cigarette smoking causes sequestration of polymorphonuclear leukocytes released from the bone marrow in lung microvessels. Am J Respir Cell Mol Biol 1999, 20:171-177.
24. Kullo IJ, Edwards WD, Schwartz RS Vulnerable plaque: pathobiology and clinical implications. Ann Intern Med 1998, 129:1050-1060.
25. Buffon A, Biasucci LM, Liuzzo G, et al. Widespread coronary inflammation in unstable angina. N Engl J Med 2002, 347:5-12.
26. Van Eeden S, Leipsic J, Paul Man SF, et al. The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med 2012, 186:11-16.
27. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004, 351:2611-2618.
28. Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010, 137:1091-1097.
29. Nemmar A, Hoylaerts MF, Hoet PH, et al. Possible mechanisms of the cardiovascular effects of inhaled particles: systemic translocation and prothrombotic effects. Toxicol Lett 2004, 149:243-253.
30. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med 2007, 175:458-463.
31. Leone N, Courbon D, Thomas F, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med 2009, 179:509-516.
32. Falk JA, Kadiev S, Criner GJ, et al. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008, 5:543-548.
33. Fabbri LM, Beghe B, Agusti A Cardiovascular mechanisms of death in severe COPD exacerbation: time to think and act beyond guidelines. Thorax 2011, 66:745-747.
34. de Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 2007, 132:1932-1938.
35. Mannino DM, Aguayo SM, Petty TL, et al. Low lung function and incident lung cancer in the United States: data from the first National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003, 163:1475-1480.
36. Turner MC, Chen Y, Krewski D, et al. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med 2007, 176:285-290.
37. Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 2008, 178:738-744.
38. Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J 2009, 34:380-386.
39. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14·5-year mortality: a randomized clinical trial. Ann Intern Med 2005, 142:233-239.
40. de Torres JP, Marin JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease-incidence and predicting factors. Am J Respir Crit Care Med 2011, 184:913-919.
41. Spira A, Beane J, Shah V, et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci USA 2004, 101:10143-10148.
42. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594.
43. Sato M, Shames DS, Gazdar AF, et al. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007, 2:327-343.
44. Spira A, Beane JE, Shah V, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 2007, 13:361-366.
45. Sato M, Shames DS, Hasegawa Y Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. Respirology 2012, 17:1048-1059.
46. Pillai SG, Ge D, Zhu G, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009, 5:e1000421.
47. Truong T, Hung RJ, Amos CI, et al. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst 2010, 102:959-971.
48. Wauters E, Smeets D, Coolen J, et al. The TERT-CLPTM1L locus for lung cancer predisposes to bronchial obstruction and emphysema. Eur Respir J 2011, 38:924-931.
49. Young RP, Whittington CF, Hopkins RJ, et al. Chromosome 4q31 locus in COPD is also associated with lung cancer. Eur Respir J 2010, 36:1375-1382.
50. Young RP, Hopkins RJ, Whittington CF, et al. Individual and cumulative effects of GWAS susceptibility loci in lung cancer: associations after sub-phenotyping for COPD. PLoS One 2011, 6:e16476.
51. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008, 358:1118-1128.
52. Hu Z, Chen J, Tian T, et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 2008, 118:2600-2608.
53. Rauch TA, Zhong X, Wu X, et al. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci USA 2008, 105:252-257.
54. Schembri F, Sridhar S, Perdomo C, et al. MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc Natl Acad Sci USA 2009, 106:2319-2324.
55. Liu F, Killian JK, Yang M, et al. Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene 2010, 29:3650-3664.
56. Guzman L, Depix MS, Salinas AM, et al. Analysis of aberrant methylation on promoter sequences of tumor suppressor genes and total DNA in sputum samples: a promising tool for early detection of COPD and lung cancer in smokers. Diagn Pathol 2012, 7:87.
57. Rooney C, Sethi T The epithelial cell and lung cancer: the link between chronic obstructive pulmonary disease and lung cancer. Respiration 2011, 81:89-104.
58. Balkwill F, Mantovani A Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
59. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006, 24:5216-5222.
60. Parimon T, Chien JW, Bryson CL, et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:712-719.
61. Walser T, Cui X, Yanagawa J, et al. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc 2008, 5:811-815.
62. Adcock IM, Caramori G, Barnes PJ Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration 2011, 81:265-284.
63. Welsh TJ, Green RH, Richardson D, et al. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005, 23:8959-8967.
64. Sekine Y, Yamada Y, Chiyo M, et al. Association of chronic obstructive pulmonary disease and tumor recurrence in patients with stage IA lung cancer after complete resection. Ann Thorac Surg 2007, 84:946-950.
65. Ueda K, Jinbo M, Li TS, et al. Computed tomography-diagnosed emphysema, not airway obstruction, is associated with the prognostic outcome of early-stage lung cancer. Clin Cancer Res 2006, 12:6730-6736.
66. Ohara T, Hirai T, Muro S, et al. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 2008, 134:1244-1249.
67. Sin DD, Man JP, Man SF The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003, 114:10-14.
68. Graat-Verboom L, Wouters EF, Smeenk FW, et al. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J 2009, 34:209-218.
69. Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the Towards a Revolution in COPD Health study. Chest 2009, 136:1456-1465.
70. Graat-Verboom L, van den Borne BE, Smeenk FW, et al. Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. J Bone Miner Res 2011, 26:561-568.
71. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:1259-1265.
72. Gosselink R, Troosters T, Decramer M Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med 1996, 153:976-980.
73. Hamilton AL, Killian KJ, Summers E, et al. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med 1995, 152:2021-2031.
74. Seymour JM, Spruit MA, Hopkinson NS, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 2010, 36:81-88.
75. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006, 173:1390-1413.
76. Decramer M, Gosselink R, Troosters T, et al. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997, 10:417-423.
77. Marquis K, Debigare R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166:809-813.
78. Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 171:972-977.
79. Watz H, Waschki B, Meyer T, et al. Physical activity in patients with COPD. Eur Respir J 2009, 33:262-272.
80. Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003, 58:752-756.
81. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011, 140:331-342.
82. Decramer M, Lacquet LM, Fagard R, et al. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994, 150:11-16.
83. Van Vliet M, Spruit MA, Verleden G, et al. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172:1105-1111.
84. Muscaritoli M, Anker SD, Argiles J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) " cachexia-anorexia in chronic wasting diseases" and " nutrition in geriatrics" Clin Nutr 2010, 29:154-159.
85. Donahoe M, Rogers RM, Wilson DO, et al. Oxygen consumption of the respiratory muscles in normal and in malnourished patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989, 140:385-391.
86. Nguyen LT, Bedu M, Caillaud D, et al. Increased resting energy expenditure is related to plasma TNF-alpha concentration in stable COPD patients. Clin Nutr 1999, 18:269-274.
87. Cohen RI, Marzouk K, Berkoski P, et al. Body composition and resting energy expenditure in clinically stable, non-weight-losing patients with severe emphysema. Chest 2003, 124:1365-1372.
88. Raguso CA, Luthy C Nutritional status in chronic obstructive pulmonary disease: role of hypoxia. Nutrition 2011, 27:138-143.
89. Koehler F, Doehner W, Hoernig S, et al. Anorexia in chronic obstructive pulmonary disease-association to cachexia and hormonal derangement. Int J Cardiol 2007, 119:83-89.
90. Creutzberg EC, Schols AM, Weling-Scheepers CA, et al. Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:745-752.
91. Chaiban JT, Bitar FF, Azar ST Effect of chronic hypoxia on leptin, insulin, adiponectin, and ghrelin. Metabolism 2008, 57:1019-1022.
92. Wust RC, Degens H Factors contributing to muscle wasting and dysfunction in COPD patients. Int J Chron Obstruct Pulmon Dis 2007, 2:289-300.
93. Lehouck A, Boonen S, Decramer M, et al. COPD, bone metabolism, and osteoporosis. Chest 2011, 139:648-657.
94. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012, 380:37-43.
95. Kirkwood TB Understanding the odd science of aging. Cell 2005, 120:437-447.
96. Faner R, Rojas M, MacNee W, et al. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012, 186:306-313.
97. Morla M, Busquets X, Pons J, et al. Telomere shortening in smokers with and without COPD. Eur Respir J 2006, 27:525-528.
98. Alder JK, Guo N, Kembou F, et al. Telomere length is a determinant of emphysema susceptibility. Am J Respir Crit Care Med 2011, 184:904-912.
99. Amsellem V, Gary-Bobo G, Marcos E, et al. Telomere dysfunction causes sustained inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 184:1358-1366.
100. Mocellin S, Verdi D, Pooley KA, et al. Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis. J Natl Cancer Inst 2012, 104:840-854.
101. Ito K, Barnes PJ COPD as a disease of accelerated lung aging. Chest 2009, 135:173-180.
102. Baur JA, Ungvari Z, Minor RK, et al. Are sirtuins viable targets for improving healthspan and lifespan?. Nat Rev Drug Discov 2012, 11:443-461.
103. Rajendrasozhan S, Yang SR, Kinnula VL, et al. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177:861-870.
104. Yao H, Chung S, Hwang JW, et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J Clin Invest 2012, 122:2032-2045.
105. Salpeter S, Ormiston T, Salpeter E Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005, 4. CD003566.
106. Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010, 170:880-887.
107. Etminan M, Jafari S, Carleton B, et al. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med 2012, 12:48.
108. Stefan MS, Rothberg MB, Priya A, et al. Association between beta-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012, 67:977-984.
109. Short PM Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011, 342:d2549.
110. Brunelli A, Charloux A, Bolliger CT, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009, 34:17-41.
111. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409.
112. Jones A, Fay JK, Burr M, et al. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002, 1. CD003537.
113. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300:2407-2416.
114. Troosters T, Casaburi R, Gosselink R, et al. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172:19-38.
115. Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177:1207-1214.
116. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009, 151:517-527.
117. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694. for the M2-124 and M2-125 study groups.
118. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009, 374:695-703. for the M2-127 and M2-128 study groups.
119. Cindy Ng LW, Mackney J, Jenkins S, et al. Does exercise training change physical activity in people with COPD? A systematic review and meta-analysis. Chron Respir Dis 2012, 9:17-26.
120. Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:948-955.
121. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
122. Vestbo J, Anderson J, Brook RD, et al. The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. Eur Respir J 2012, published online Sept 27. 10.1183/09031936.00087312.
123. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010, 137:20-30.
124. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006, 47:2554-2560.
125. Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009, 10:45.
126. van Gestel YR, Hoeks SE, Sin DD, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 2008, 102:192-196.
127. Dobler CC, Wong KK, Marks GB Associations between statins and COPD: a systematic review. BMC Pulm Med 2009, 9:32.
128. Janda S, Park K, FitzGerald JM, et al. Statins in COPD: a systematic review. Chest 2009, 136:734-743.
129. Hothersall E, McSharry C, Thomson NC Potential therapeutic role for statins in respiratory disease. Thorax 2006, 61:729-734.
130. Ridker PM, Danielson E, Fonseca FAH, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373:1175-1182. for the the JUPITER Trial Study Group.
131. van Gestel YR, Hoeks SE, Sin DD, et al. COPD and cancer mortality: the influence of statins. Thorax 2009, 64:963-967.